What the Latest Dementia Study Says about Links with Certain Medicines

Home » Blog » What the Latest Dementia Study Says about Links with Certain Medicines
June 23, 2022 •  The Estate & Elder Law Center of Southside Virginia, PLLC
Controversy regarding the purported link between the use of proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2RAs) and risk for dementia continues.
Robert W. Haley, managing lawyer
Robert W. Haley
Certified Elder Law Attorney® Robert W. Haley brings over 27 years of legal expertise and knowledge to his firm, which concentrates solely on the areas of elder law, estate planning (Last Will & Testaments, Durable Powers of Attorney, Health Care Powers of Attorney, Living Wills, Trusts, etc.,.) Asset Protection/Medicaid Planning and fiduciary services. For many years, Robert practiced in real estate law, and in general practice, but decided to narrow his focus to elder law and estate planning when he realized the tremendous need for proper planning to be filled in Southside Virginia.

MedScape’s recent article entitled “More Evidence Dementia Not Linked to PPI Use in Older People” reports that among nearly 19,000 people, no link was found between the use of proton pump inhibitors (PPIs) or histamine H2 receptor antagonists (H2Ras) and a greater likelihood of incident dementia, Alzheimer's disease, or cognitive decline in people older than 65 years.

"We found that baseline PPI or H2RA use in older adults was not associated with dementia, with mild cognitive impairment, or declines in cognitive scores over time," said lead author Raaj Shishir Mehta, MD, a gastroenterology fellow at Massachusetts General Hospital in Boston.

"While deprescribing efforts are important, especially when medications are not indicated, these data provide reassurance about the cognitive impacts of long-term use of PPIs in older adults," he added.

As PPI use has increased worldwide, so too have concerns over the adverse effects from their long-term use, Mehta said.

"One particular area of concern, especially among older adults, is the link between long-term PPI use and risk for dementia," he said.

Behind the controversy was a February 2016 study published in JAMA Neurology that showed a positive connection between PPI use and dementia in residents of Germany aged 75 years and older.

The researchers linked PPI use to a 44% increased risk of dementia a five-year period.

This study was based on claims data, which can introduce "inaccuracy or bias in defining dementia cases," Dr. Mehta said. He commented that it and other previous studies also were limited by an inability to account for concomitant medications or comorbidities.

To overcome these limitations in their study, Dr. Mehta and colleagues examined medication data collected during in-person visits and asked experts to confirm dementia outcomes.

The research data come from ASPREE, a large aspirin study of 18,846 people 65+ in the United States and Australia. Participants were enrolled from 2010 to 2014, and a total of 566 people developed incident dementia during follow-up.

The researchers had data on alcohol consumption and other lifestyle factors, along with data on comorbidities, hospitalizations and overall well-being.

Reference: MedScape (May 24, 2022) “More Evidence Dementia Not Linked to PPI Use in Older People”

Book an Initial Call
Speak With Someone
Schedule an available time to speak with us. We look forward to meeting with you!
Book an Initial Call
Client Success Stories
Google Reviews
Danville Virginia Office

742 Main Street,
Danville, Virginia 24541

Bassett Virginia Office

1460 Fairystone Park Hwy,
Bassett, Virginia 24055

Lynchburg Virginia Office

810 Main Street, (3rd Floor of the Truist Building)
Lynchburg, Virginia 24504

Integrity Marketing Solutions - Estate Planning Marketing
Powered by
magnifiercrosschevron-down